AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
AngioDynamics to Report Fiscal 2020 Third Quarter Financial Results on April 7, 2020
Mar 10, 2020 @ 20:01
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2020 before the market open on Tuesday, April...
AngioDynamics to Present at Two Investor Conferences in March
Feb 27, 2020 @ 21:01
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will present at the following two investor conferences in March:...
AngioDynamics investing $7 million in Glens Falls and Queensbury
Feb 26, 2020 @ 11:00
"If you are interested in three quarters or four quarters, we might not be your company to invest in," CEO Jim Clemmer said. "If you are interested in three or four or five years, that's what we are building here."...
AngioDynamics Appoints Stephen Trowbridge Executive Vice President and Chief Financial Officer
Feb 06, 2020 @ 13:00
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it has appointed Stephen Trowbridge to the role of Executive Vice President and Chief Financial Officer, effective...
AngioDynamics Launches PATHFINDER I Registry to Evaluate Performance and Clinical Outcomes of the AURYON™ Atherectomy System
Jan 16, 2020 @ 16:00
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced the launch of the PATHFINDER I: Post-Market Registry (PATHFINDER I-Registry, EX-PAD-05), a pilot study to evaluate the...
AngioDynamics' latest acquisition will boost $95 million business line
Jan 08, 2020 @ 11:00
It is the latest in a string of acquisitions for AngioDynamics as chief exec Jim Clemmer refocuses the medical device maker by "carving out significant space in larger and faster growing markets."...